MicroRNA-1182 and let-7a exert synergistic inhibition on invasion, migration and autophagy of cholangiocarcinoma cells through down-regulation of NUAK1

Xin Pan*, Gang Wang and Baoming Wang

Abstract

Background: Cholangiocarcinoma (CCA) is the second most common primary liver malignancy worldwide. Several microRNAs (miRNAs) have been implicated as potential tumor suppressors in CCA. This study aims to explore the potential effects of miR-1182 and let-7a on CCA development.

Methods: Bioinformatics analysis was conducted to screen differentially expressed genes in CCA, Western blot analysis detected NUAK1 protein expression and RT-qPCR detected miR-1182, let-7a and NUAK1 expression in CCA tissues and cell lines. Dual luciferase reporter gene assay and RIP were applied to validate the relationship between miR-1182 and NUAK1 as well as between let-7a and NUAK1. Functional experiment was conducted to investigate the role of miR-1182, let-7a and NUAK1 in cell migration, proliferation and autophagy. Then, the CCA cells that received various treatments were implanted to mice to establish animal model, followed by tumor observation and HE staining to evaluate lung metastasis.

Results: CCA tissues and cells were observed to have a high expression of NUAK1 and poor expression of miR-1182 and let-7a. NUAK1 was indicated as a target gene of miR-1182 and let-7a. Importantly, upregulation of either miR-1182 or let-7a induced autophagy, and inhibited cell progression and in vivo tumor growth and lung metastasis; moreover, combined treatment of miR-1182 and let-7a overexpression presented with enhanced inhibitory effect on NUAK1 expression and CCA progression, but such synergistic effect could be reversed by overexpression of NUAK1.

Conclusion: Taken together, the findings suggest the presence of a synergistic antitumor effect of miR-1182 and let-7a on the development of CCA via the down-regulation of NUAK1, providing novel insight into the targeted therapy against CCA.

Keywords: MicroRNA-1182, Let-7a, NUAK1, Cholangiocarcinoma, Invasion, Migration, Autophagy

Background

As the second-most common primary hepatobiliary malignancy, cholangiocarcinoma (CCA) generally occurs as a result of long-standing inflammation, injury and reparative biliary epithelial cell proliferation [1, 2]. The high mortality of CCA is explained by the extreme difficulty associated with the diagnosis of CCA at an early stage, along with high frequency of recurrence and metastasis and lack of effective chemotherapeutic, surgical or other treatment options [3]. The risk factors of CCA include cirrhosis and viral hepatitis B and C [4]. On the other hand, overexpression of inflammatory genes, cytokines or STAT3, could result in the...
development of CCA, especially intrahepatic cholangiocarcinoma (ICC). Additionally, strong correlations have been identified between CCA and genetic mutations in patients [5]. Several genes have been considered as potential therapeutic targets in CCA secondary to their independent prognostic values, such as VDR, CYP7A, CD147 and HER4 [6, 7]. Nevertheless, the therapeutic and diagnostic potential of these genes requires further large-scale investigations.

As a member of the human adenosine monophosphate-activated protein kinases family, NUAK1 (also known as ARK5, AMPK-related kinase 5) has been observed to have a high expression in multiple human malignancies, and participates in tumor invasion, migration, survival and progression [8, 9]. For example, NUAK1 is highly expressed in non-small cell lung cancer (NSCLC) and knockdown of this gene served as a block in lung metastasis and invasive ability in a xenograft mouse model [8]. Moreover, NUAK1 is a valuable molecular biomarker for gastric cancer progression, since its suppression can prevent cell invasion, lymph node metastasis, pathological stage and histological differentiation [10]. miRNAs are endogenous noncoding RNAs that serve as modulators of gene expression and their dysregulation has been linked with the development of inflammatory-driven carcinogenesis [11]. Numerous studies have emphasized the tumor suppressor or promoter role of miRNAs, which might function in the tumorigenic process of malignant tumors such as CCA [3, 12–14]. In pancreatic cancer, NUAK1 is specifically up-regulated and the down-regulation by miR-96 is capable of impeding the proliferation, migration and invasion of Mia PaCa-2 pancreatic cancer cells [15]. In addition, NUAK1 level has been shown to be significantly increased in ICC tissues and cell lines while miR-145 expression was significantly decreased; moreover, NUAK1 was also identified as a direct target of miR-145 regulation, aiding the prevention of ICC progression [16]. Autophagy may be related to the development of CCA [17]. As autophagy is essential in numerous physiologies, ranging from immune response to neuronal health, its activation is key in the carcinogenesis of CCA progression [18]. Pietri Puustinen et al. demonstrated the presence of a close correlation between NUAK1 and autophagy [19], whilst Chen et al. suggested that the inhibition of NUAK1 suppressed autophagy as indicated by the decreased expression of MMP-2, matrix metalloproteinase (MMP)-2 and MMP-9 [8]. However, the interaction between NUAK1 and autophagy remains unclear. These findings led to the hypothesis that there existed a promising correlation between NUAK1 and other miRNAs in CCA. Therefore, the present study focused on exploring the correlations between the expression of miR-1182 and let-7a and CCA cell migration, invasion and autophagy with aims of discovering a promising therapeutic strategy for CCA.

**Materials and methods**

**Ethical statement**

This study was carried out in strict accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Institutional Animal Care and Use Committee of The Fourth Affiliated Hospital of China Medical University.

**Bioinformatics analysis**

Differentially expressed genes (DEGs) were screened using CAA-related gene expression profile downloaded from the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/) and R language "limma" package with threshold set as |logFC|>2 and \( p<0.05\). DEGs were presented in a heatmap by using "pheatmap" package. Subsequently, the expression of NUAK1 in the CCA samples collected in The Cancer Genome Atlas (TCGA) was analyzed based on the UALCAN database (http://ualcan.path.uab.edu/index.html). Next, CCA related genes were retrieved in the Malacards database (http://www.malacards.org/), and their interaction with NUAK1 was further analyzed in the STRING database (https://string-db.org/). Finally, the RNA22 database (https://cm.jefferson.edu/rna22/Precomputated/) and miRGator database (http://mirgator.kobic.re.kr/) were performed to predict the miRNAs that regulated NUAK1. The intersection of the first 80 miRNAs from the result obtained from the above two databases was analyzed using the Venn diagram website (http://bioinformatics.psb.ugent.be/webtools/Venn/).

**Study subjects**

A total of 56 patients confirmed as hilar CCA by surgery and pathology from January 2018 to December 2018 in The Fourth Affiliated Hospital of China Medical University were enrolled as study subject, including 34 males and 22 females, aged 35–78 years old. According to tumor nodes metastasis (TNM) stage of Union for International Cancer Control, there are 22 cases of stage I-II and 34 cases of III-IV. According to the degree of differentiation, 20 cases had poor differentiation, 19 cases had moderate differentiation, and 17 cases had high differentiation. Meanwhile, 32 cases of bile duct tissues were obtained from patients with hepatic trauma specimen and served as control.

Human normal biliary epithelial cell line HIBEPIC and CCA cell lines (CCC-5, HCC-9810, Huh28) from BeNa Culture Collection (Beijing, China) were detected by mycoplasma and identified by short tandem repeat
(STR) genotyping (Additional file 1; Table S1). Cells were cultured in dulbecco's modified eagle medium (DMEM) medium (QBC939) or a Roswell Park Memorial Institute cultured in dulbecco's modified eagle medium (DMEM) containing 10% serum at 37 °C in a 5% CO₂ incubator and were sub-cultured upon the cells reaching 80–90% confluence. A reverse transcription quantitative polymerase chain reaction (RT-qPCR) was applied to screen out the cell line with the lowest expression of miR-1182 and let-7a for subsequent experiments.

Dual-luciferase reporter gene assay
The bioinformatics website (http://microRNA.org) identified NUAK1 as the target gene of miR-1182 and let-7a, after which their binding relationship was determined using dual-luciferase reporter gene assay. Wild type (WT) and mutated (MUT) NUAK1 3′UTR gene fragment containing miR-1182 or let-7a binding target was synthesized. The synthesized fragments were cloned into a pMIR-REPORT plasmid (Guangzhou RiboBio Co., Ltd., Guangdong, China) with application of restriction enzyme. Then the plasmids were co-transfected with miR-1182 mimic, let-7a mimic, or mimic NC into HCCC-9810 and Huh28 cells. Before transfection, HCCC-9810 and Huh28 cells were seeded onto 6-well plates (3 × 10⁵ cells/well) and when cell confluency reached 80%, cells were transfected with miR-1182 mimic or a Roswell Park Memorial Institute cultured in dulbecco's modified eagle medium (DMEM) medium (QBC939) or a Roswell Park Memorial Institute cultured in dulbecco's modified eagle medium (DMEM) containing 10% serum at 37 °C in a 5% CO₂ incubator and were sub-cultured upon the cells reaching 80–90% confluence. A reverse transcription quantitative polymerase chain reaction (RT-qPCR) was applied to screen out the cell line with the lowest expression of miR-1182 and let-7a for subsequent experiments.

RNA isolation and quantification
Total RNA was extracted from tumor tissues with the use of miRNeasy Mini Kit (217,004, Qiagen, Hilden, Germany). Then the total RNA was reversely transcribed into cDNA (10 μL) using the Primerscript™ RT reagent Kit (RRO36A, Takara Biotechnology Ltd., Dalian, Liaoning Province, China). All the samples were performed using a SYBR® Premix Ex Taq™ II reagent kit (RR820A, Takara) on an ABI7500 real-time quantitative PCR system (ABI Company, Oyster Bay, NY, USA) with a reaction system (50 μL) consisting of SYBR® Premix Ex TaqTM II (2 ×) 25 μL, PCR upstream primer 2 μL, PCR downstream primer 2 μL, ROX Reference Dye (50 ×) 1 μL, cDNA template 4 μL, and ddH₂O 16 μL. The primers were all synthesized by Takara and are listed in Table 1. The fold changes were calculated using the relative quantification (2^−ΔΔCt method) with 2 μg RNA as template and Glyceroldehyde-3-phosphate dehydrogenase (GAPDH) or U6 as internal reference.

Table 1 Primer sequences for RT-qPCR

| Gene       | Sequence (5′-3′)                        |
|------------|-----------------------------------------|
| miR-1182   | F: GGGAGGGGTCTTGGGAAGGA                  |
|            | R: GTGCAGGTCGGAGGT                     |
| miR-let-7a | F: TGAGTTAGGTTGTTGTTGTTT                |
|            | R: GTGCAGGTCGGAGGT                     |
| NUAK1      | F: GAAATGATGCTTTATTTCAC                 |
|            | R: CACCTCTCTGATTCTAGGTT                |
| MMP-2      | F: AGTTTCCATCGGTTCACC                   |
|            | R: CCGTTGTAATGCTTCACTGTTG             |
| MMP-9      | F: ACTACTGTCCTTGTAGTCC                 |
|            | R: AGAACTGCCGACTTCCCA                  |
| Beclin1    | F: ATGCAGGTTAGCTCCTGTTG                |
|            | R: CTGGGCTGTCTAAGTATGCGA               |
| LC3        | F: AATCCCCGGTAGCTACGAGC                |
|            | R: GCCCGGAGTACTCTTGACCAA               |
| U6         | F: ATTTGAAAGCATACAGAAAGATT             |
|            | R: GGAGCGCTTACCGAGATT                 |
| GAPDH      | F: GGAGAACTCTGGCGTGTAT                 |
|            | R: GAGTTGAGTCCGCTGTTGA                |

RT-qPCR reverse transcription quantitative polymerase chain reaction, MiR-1182 mimicRNA-1182, miR-let-7a mimicRNA-let-7a, NUAK1 Novel (nua) kinase family 1, MMP-2 matrix metalloproteinase-2, MMP-9 matrix metalloproteinase-9, IC3 light chain 3, GAPDH glyceroldehyde-3-phosphate dehydrogenase
Western blot analysis

Cells at logarithmic growth phase were lysed. Afterwards, the cell lysates were separated by 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a polyvinylidene fluoride membrane. The membranes were blocked with 5% skim milk for 1 h at room temperature and incubated with diluted primary antibodies purchased from Abcam Inc.(Cambridge, UK): rabbit polyclonal antibody to NUAK1 (1: 500, ab71814), rabbit polyclonal antibody to matrix metallopeptidase 2 (MMP-2, 2.0 µg/mL, ab37150), rabbit polyclonal antibody to MMP-9 (1.0 µg/mL, ab73734), rabbit polyclonal antibody to light chain 3 beta (LC3B) (1.0 µg/mL, ab51520), and rabbit monoclonal antibody to Beclin1 (1: 2000, ab207612). This was followed by incubation with the horseradish peroxidase (HRP)-conjugated goat anti-mouse immunoglobulin G (IgG) secondary antibody (1: 100; HA1003, Shanghai Yanhui Biotechnology Co., Ltd., Shanghai, China) for 1 h. Finally, the enhanced chemiluminescence reagent (ECL808-25, Biomiga, San Diego, CA, USA) was used to visualize the results by the X-ray film (36209ES01, QcbioScience & Technology Co., Ltd., Shanghai, China), with GAPDH serving as an internal control.

RNA binding protein immunoprecipitation (RIP)

RIP kit (Millipore, USA) was used to detect the binding potential of NUAK1 mRNA and miR-1182 or let-7a. Cells were lysed with an equal volume of RIPA lysate (P0013B, Biyuntian, Shanghai, China) in an ice bath for 5 min, followed by centrifugation at 14,000 rpm for 10 min at 4 °C, with the supernatant obtained. Part of the cell extract was used as the input, while the remainder was incubated with antibodies for co-precipitation. For each co-precipitation reaction system, 50 µL magnetic beads were resuspended in 100 µL RIP Wash Buffer and incubated with 5 µg antibody against NUAK1 (1 µg/ml, ab23738) or IgG (1:100, ab172730). After washing, the magnetic bead-antibody complex was re-suspended in 900 µL RIP Wash Buffer, and interacted with 100 µL cell extract at 4°C overnight. The magnetic bead-antibody complex and Input were digested with proteinase K, from which RNA was extracted for subsequent PCR detection. Argonaute2 (Ago2) is the key factor of Ago2 RIP-seq, and Ago2 is also a core component and effector protein of miRISC silencing complex (miRNA-induced silencing complex), which participates in the gene silencing effect mediated by miRNA and siRNA [20, 21]. Therefore, detecting the binding of miR-1182, let-7a, NUAK1 and AGO2 protein can reflect whether miR-1182, let-7a, and NUAK1 belong to the same RNA-induced silencing complex (RISC), and indirectly indicate the binding between miR-1182, let-7a and NUAK1 mRNA.

Cell counting kit-8 (CCK-8) assay

After transfection for 48 h, the cells were prepared into single cell suspension and suspension was seeded in a 96-well plate (1 × 10^4/mL) with sex duplicated wells set and incubated in an incubator at 37°C for 24 h. Next, the plate was added with CCK-8 solution (Hyclone, South Logan, UT, USA) and underwent additional incubation for 2 h. The absorbance (A) value was measured at 450 nm with a microplate reader.

Scratch test

After 48 h of cell transfection, cells were seeded in 6-well plates at a density of 5 × 10^4 cells/well. When cells reached 90% confluence, the scratches were made with a sterile pipette tip. Then the floating cells were washed off with PBS, after which serum-free medium was added for further 0.5–1 h culture to promote cell recovery. With the recovery time used as the start, cells were photographed at 0 h and 24 h respectively, and the cell migration distance was measured using the Image-Pro Plus Analysis software (Media Cybernetics, Inc., Washington Street, Boston, MD, USA).

Transwell assay

The cell invasion was evaluated by Matrigel invasion assay. 50 mg/L Matrigel (corning, USA) was diluted in 0.5% FBS in DMEM medium at a ratio 1:6. Then, the Matrigel gel (60 µL) was added to upper chamber of the bottom membrane of the Transwell chamber using pipette, followed by rinsing to aspirate the excess gel. Then the chamber was placed in the incubator for 4 h. After 48 h of cell transfection, cell suspension was prepared through cell digestion. Then the suspension was seeded to apical chamber (1 × 10^6 cells/well) and incubation was carried out in a serum-free medium for 24 h at 37 °C and the basolateral chamber was added with a medium containing 10% FBS. The invasive cells on the lower side of the filter were fixed with 5% glutaraldehyde, stained with 0.1% crystal violet, and counted under a microscope from 5 random fields.

Monodansylcadaverine (MDC) staining

The prepared cell suspension was added into a 6-well plate (1 × 10^5 cells/well) containing pre-treated sterile coverslips and cultured for 24 h at 37 °C in a 5% CO₂ incubator. Then the cells were stained with MDC dye (2 µL/well) for 20 min, and fixed in 2 mL 4% paraformaldehyde for 15 min. After removal of paraformaldehyde, the cells were placed in the center of the coverslip (added
with the prepared glycerol). Finally, the coverslip was observed under a fluorescence microscope.

**Immunohistochemistry (IHC)**

The CCA tissue sample was fixed with 4% paraformaldehyde, embedded and sliced to Sections (5 μm) and the sections were routinely dewaxed and subjected to antigen retrieval by the application of heat. The sections were washed with PBS and blocked in 5% goat serum for 15 min. Then the sections were incubated with primary antibody rabbit polyclonal antibody NUAK1 (1:100, ab203591, Abcam, UK) overnight at 4 °C and biotinylated goat anti rabbit secondary antibody (1:1000, ab6720, Abcam, UK) for 1 h at room temperature. The sections were incubated horseradish peroxidase-conjugated solution for 15 min, washed twice with 0.01 mol/L (pH=7.4) PBS and developed with 3,3-diaminobenzidine tetrahydrochloride (DAB) solution (Beijing Zhongshan Jinqiao Biotechnology Co., Ltd.) for 3–5 min. Then the samples were counter-stained with hematoxylin for 1–3 min, dehydrated, cleared and sealed neutral gum mount. The sections were observed and photographed under a Primo Star digital microscope (purchased from McAudi Industrial Group Co., Ltd., Guangzhou, China) through 5 random high-power fields. Positive cells (yellow) were counted and the ratio was calculated: Protein positive rate = number of positive cases/total number of cases × 100%.

**Xenograft model of CCA and pulmonary metastasis tumor model**

CCA cells were infected with lentivirus expressing miR-1182 agomire, agomir-NC, miR-let-7a agomir, and miR-1182 agomir +let-7a agomir, respectively. Stably transfected cells (1 × 10⁶; 200 μL) were then inoculated at their right hind leg back of 32 nude mice (n=8, each group), under anesthesia with 3% pentobarbital sodium. Then the mice were observed once every 7 d to record the length and width of the tumor. The tumor volume was measured as follows: Tumor volume = (length × width)^2/2. At the 35th day, the mice were euthanatized to collect the tumors (3 tumor samples in each group). The tumors were weighed and recorded. At the same time, the lung tissues of nude mice were obtained and fixed in formalin, embedded in paraffin and cut into sections. Then the sections were subjected to HE staining and observed under a microscope to detect the tumor formation of CCA in the lung tissues.

**Statistical analysis**

All data were analyzed using a Statistic Package for Social Science (SPSS) 21.0 statistical software (IBM Corp. Armonk, NY, USA). The measurement data were described as mean± standard deviation. Comparisons between two groups in an unpaired design were analyzed using unpaired t-test. Comparisons among multiple groups were analyzed using the one-way analysis of variance (ANOVA) and followed by Tukey’s post hoc test. The tumor volume changes were compared with two-way ANOVA and followed by Bonferroni post hoc test. Pearson correlation was used to analyze the correlation between two groups. The enumeration data is expressed as rate and the differences between groups were verified using a chi-square test or Fisher’s exact test. A value of p < 0.05 was considered to be statistically significant.

**Results**

**NUAK1 is highly expressed in CCA samples**

Initially, the GEO database was used for the retrieval of CCA related microarray data, after which GSE45001 microarray was obtained. The differences between CCA samples and normal samples were analyzed, and finally 1083 DEGs were obtained. Among them, 404 up-regulated genes were found in CCA along with 679 markedly down-regulated genes. Figure 1a shows an expression heat map of 30 DEGs in the microarray. Among these DEGs, significant up-regulation of NUAK1 gene expression was observed in the CCA samples. Through the GEO database, another CCA-related microarray data GSE89749 was observed, in which the NUAK1 gene was analyzed (Fig. 1b). The results showed significantly increased NUAK1 expression in CCA (p<0.05). The NUAK1 gene expression was further explored in the TCGA-listed CCA database (Fig. 1c), and the results showed that CCA had up-regulated NUAK1 expression. To further confirm the relationship between the NUAK1 gene and CCA, the GeneCards database displayed that one CCA-related gene, tumor protein 53 (TP53), was found to be at the core of the network map, indicating a clear intersection with NUAK1 gene (Fig. 1d). These analyses indicate that NUAK1 is likely to be involved in the development of CCA. To study the upstream regulatory mechanism of NUAK1, the miRNA that can regulate NUAK1 was predicted using the RNA22 and miRGator databases. From intersection of prediction results, there were only two miRNAs, hsa-let-7a and hsa-miR-1182 (Fig. 1e). These analyses suggest that hsa-let-7a and hsa-miR-1182 are highly likely to influence the development of CCA via NUAK1 regulation.

**Differential expression of miR-1182, let-7a and NUAK1 in CCA**

To determine whether miR-1182, let-7a and NUAK1 are differentially expressed in CCA, Immunohistochemistry was first used to identify NUAK1 expression in CCA tissues and controls, the results of which found
that NUAK1 was highly expressed in CCA tissues relative to normal tissues (Fig. 2a). RT-qPCR analysis was subsequently performed to determine the expressions of miR-1182, let-7a and NUAK1 in CCA tissues and controls. CCA tissues presented with downregulated expression of miR-1182 and let-7a compared with that of normal tissues, whilst the expression of NUAK1 was up-regulated. Moreover, the aberrant expression of miR-1182, let-7a and NUAK1 was more prominent in the III-IV phase relative to TNM I-II phase (Fig. 2b, c). Pearson correlation analysis showed that there existed a negative correlation between miR-1182 and let-7a and the expression of NUAK in CCA tissues (Fig. 2d).

The relationships between miR-1182, let-7a and clinical pathological features of patients with CCA were further explored. The expression of miR-1182 and let-7a showed no significant difference from the age, sex and tumor size of patients, but their expression was significantly correlated with patient TNM staging, degree of differentiation and lymph node metastasis (LNM) \((p < 0.05, \text{Table } 2)\). Furthermore, the expression of miR-1182, let-7a and NUAK1 was determined in human normal biliary epithelial cell line HIEPIC and CCA cell lines CCC-5, HCCC-9810, Huh28. Using Western blot and RT-qPCR analyses, the results of which showed decreased expression of miR-1182 and let-7a and
increased expression of NUAK1 in CCA cells (Fig. 2e, f).

**NUAK1 mRNA binds to miR-1182 and let-7a**

The relationship between NUAK1 and let-7a and miR-1182 is displayed in Fig. 3a. Dual-luciferase reporter gene assay was carried out to verify whether miR-1182 and let-7a can target NUAK1. The results showed a decrease in the luciferase activity of pNUAK1-WT in HCCC-9810 and Huh28 cells upon treatment with miR-1182 mimic and let-7a mimic (p < 0.05). However, when the same experiment was conducted with MUT pNUAK1, there was no significant change observed in luciferase activity in the presence of miR-1182 mimic and let-7a mimic (p > 0.05). This indicated that NUAK1 mRNA can specifically bind to miR-1182 and let-7a (Fig. 3b). In addition, the binding between miR-1182, let-7a and NUAK1 mRNA was identified with the application of RIP experiments, which revealed that miR-1182 or let-7a resulted in the significant enrichment of NUAK1 (Fig. 3c). The aforementioned findings indicate that miR-1182 and let-7a can bind to NUAK1 mRNA and negatively regulate its expression.

**MiR-1182 and let-7a down-regulates NUAK1 expression in CCA cell line**

To observe the expression of miR-1182, miR-let-7a, and NUAK1 in HCCC-9810 and Huh28 cells after transfection, RT-qPCR and Western blot analysis were performed (Fig. 4). Compared with miR-NC and pc-DNA, miR-1182 mimic, let-7a mimic and miR-1182 mimic + let-7a mimic resulted in the significant increase in the expression of miR-1182; similarly, miR-let-7a mimic, miR-1182 mimic + let-7a mimic, miR-1182 mimic + let-7a mimic + NUAK1 resulted in increased miR-let-7a expression. Interestingly, NUAK1 expression was increased in cells post overexpression, while the combination of oe-NUAK1, miR-1182-mimic, and miR-let-7a-mimic restored expression of NUAK1, almost close to the level that was observed upon miR-NC or pc DNA (p > 0.05). miR-1182 mimic alone or miR-let-7a mimic resulted in the reduction of NUAK1 expression,
while combined treatment with miR-1182 mimic and let-7a mimic led to further reduction of NUAK1 expression \((p<0.05)\). The aforementioned results indicated that miR-1182 and let-7a overexpression down-regulates NUAK1 levels in HCCC-9810 and Huh28 CCA cells, and NUAK1 expression is restored after NUAK1 overexpression.

**Up-regulated miR-1182 and let-7a inhibit proliferation, migration and invasion of CCA cells**

To understand the role of miR-1182 and miR-1et-7a in progression of CAA, CCK-8 assay, Scratch test and transwell assay were carried out to detect the effects of miR-1182 and let-7a on HCCC-9810, Huh28 cell proliferation, migration and invasion. It was presented that, no significant difference in these capacities was observed in cells transfected with miR-NC and pc-DNA \((p>0.05)\). Compared with miR-NC and pc-DNA treatment, miR-1182 mimic, let-7a mimic and miR-1182 mimic + let-7a mimic weakened the capacities of migration, invasion and proliferation with treatment of miR-1182 mimic + let-7a mimic exhibiting inhibitory effect. But the presence of NUAK1 potentiated the cell progression, while simultaneously reversing the

---

**Table 2 The relationship between miR-1182, miR-let-7a and clinicopathological characteristics of patients with CCA**

| Influence factors | miR-1182 | | miR-let-7a | |
|-------------------|----------|----------|------------|----------|
|                   | High     | Low      | \(p\) value | HIGH     | LOW      | \(p\) value |
| Gender            |          |          |            |          |          |
| Male              | 34       | 20       | 0.289      | 17       | 17       | 0.74       |
| Female            | 22       | 16       |            | 10       | 12       |            |
| Age               |          |          |            |          |          |
| \(\geq 55\)       | 7        | 13       | 0.934      | 9        | 11       | 0.72       |
| \(< 55\)          | 13       | 23       |            | 18       | 18       |            |
| Tumor size        |          |          |            |          |          |
| \(\geq 2\) cm     | 6        | 10       | 0.86       | 7        | 9        | 0.672      |
| \(< 2\) cm        | 14       | 26       |            | 20       | 20       |            |
| TNM stage         |          |          |            |          |          |
| I–II              | 17       | 5        | \(<0.001\)| 18       | 4        | \(<0.001\)|
| III–IV            | 3        | 31       |            | 9        | 25       |            |
| Differentiation degree |      |          |            |          |          |
| High              | 17       | 2        | \(<0.001\)| 15       | 2        | \(<0.001\)|
| Moderate          | 19       | 15       |            | 10       | 9        |            |
| Low               | 20       | 19       |            | 2        | 18       |            |
| LNM               |          |          |            |          |          |
| Yes               | 27       | 26       | \(<0.001\)| 3        | 24       | \(<0.001\)|
| No                | 29       | 19       | 10         | 24       | 5        |            |

The expression of miR-1182 and miR-let-7a was not significantly different from the age, sex and tumor size of patients, but the expression was significantly correlated with patient TNM staging, degree of differentiation and LNM \((p<0.001)\).

*miR-1182 microRNA1182, miR-let-7a microRNA-let-7a, TNM tumor nodes metastasis, LNM lymph node metastasis*
**Pan et al. Cancer Cell Int          (2021) 21:161**

**a**

**Gene:** NUA1 | ENSG00000074590 | Internal | Ensembl Link | Transcript access 1 time(s) sine 4/1/2015

**Gene description:** NUA1 family, SNF1-like kinase, [Source:HGNC Symbol;Acc:HGNC:14311]

**External Links:** The Human Protein Atlas | Allen Institute for Brain Science | FACTA+ | Gene Expression Atlas | Gene External References

| hsa-Let-7a-5p | 5941 | 3'UTR | -17.10 | ATTAAGCACGTCCCTGCTTC TGAGGTAGTAGGTTGTATAGTT |
|-------------|------|-------|--------|----------------------------------------------|
| hsa-miR-1182 | 5858 | 3'UTR | -20.50 | TGAGGAGGATATATGTTGAGGATGTGACCTGACACTCTGCCAACATCCTC-20.50 |

**Fig. 3** NUA1 is predicted to be regulated by miR-1182 and let-7a. **a** Prediction of binding sites of miR-1182 and let-7a to NUA1 mRNA by bioinformatics analysis. **b** Dual-luciferase reporter gene assay of relative luciferase activity of pNUA1-WT and pNUA1-MUT upon treatment with let-7a mimic or miR-1182 mimic. **c** RIP experiment of relative enrichment of NUA1, miR-1182, and let-7a upon addition of IgG or Ago2 in HCCC-9810 and Huh28 cells. **d** RT-qPCR analysis of NUA1 mRNA expression upon treatment with NC, let-7a mimic or miR-1182 mimic. **e** Western blot analysis of NUA1 protein expression upon treatment with NC, let-7a mimic or miR-1182 mimic and corresponding quantification. *p < 0.05 vs. the NC group or IgG group. Statistical data were measurement data, described as mean ± standard deviation. Comparisons between two groups were analyzed by independent t-test. The experiment was repeated 3 times independently. NUA1 novel (nua) kinase family 1, miR-1182 microRNA-1182, let-7a microRNA-let-7a, NC negative control.

**Fig. 4** miR-1182 and let-7a down-regulate NUA1 expression. **a** RT-qPCR analysis of the expression of miR-1182, let-7a and NUA1 mRNA in HCCC-9810 and Huh28 cells upon treatment with miR NC, pc-DNA, miR-1182 mimic, let-7a mimic, miR-1182 mimic + let-7a mimic, miR-1182 mimic + miR-let-7a mimic + NUA1. **b** Quantification of NUA1 protein expression upon treatment with miR NC, pc-DNA, miR-1182 mimic, let-7a mimic, miR-1182 mimic + let-7a mimic, miR-1182 mimic + miR-let-7a mimic + NUA1 in HCCC-9810 and Huh28 cells. *p < 0.05 vs. that of cells transfected with miR-NC or pc-DNA, # p < 0.05 vs. that of cells transfected with miR-1182 mimic or let-7a mimic, and & p < 0.05 vs. that of cells transfected miR-1182 mimic + let-7a mimic; statistical data were measurement data, described as mean ± standard deviation. Comparisons among multiple groups were analyzed using ANOVA and followed by Tukey’s post hoc test. The experiment was repeated 3 times independently. GAPDH glyceraldehyde-3-phosphate dehydrogenase, RT-qPCR reverse transcription quantitative polymerase chain reaction.
The overexpression of NUAK1 in HCCC-9810 and Huh28 cells resulted in elevated levels of MMP-2 and MMP-9; treatment with miR-1182 mimic + let-7a mimic + NUAK1 rarely altered the level of MMPs as the level was similar to that of miR-NC or pc-DNA. Therefore, up-regulation of miR-1182 and let-7a can suppress both the migration and invasion of CCA cells, which can be reversed by NUAK1 overexpression. This indicates that miR-1182 and let-7a delays CAA cell progression through inhibition of NUAK1.
Up-regulated miR-1182 and let-7a induce autophagy of CCA cells

MDC staining was conducted to investigate the effect of miR-1182 and let-7a on cell autophagy. As results displayed, there was no significant difference in autophagy rate of cells transfected with miR-NC and pc-DNA (all p > 0.05). Compared with cells transfected with miR-NC and pc-DNA, autophagy rate was much higher in cells transfected with miR-1182 mimic, let-7a mimic and miR-1182 mimic + let-7a mimic. Combined treatment of miR-1182 mimic and let-7a mimic enhanced the promoting effect on autophagy. The autophagy fluorescence level was diminished in cells treated with NUAK1. When miR-1182 mimic + let-7a mimic + NUAK1 was treated simultaneously, the autophagy expression was restored to that level post miR-NC and pc-DNA (p > 0.05) (Fig. 6a, b).

Herein, we checked the expressions of autophagy related factors Beclin1 and LC3 using RT-qPCR and Western blot analysis upon treatment with overexpression of NUAK1 and miRNAs. The levels of Beclin1 and LC3 mRNA were increased in cells transfected with miR-1182 mimic, let-7a mimic and miR-1182 mimic + let-7a mimic, with elevated ratio of LC3II/LC3I. Following treatment with NUAK1, the mRNA expression of Beclin1 and LC3 reduced dramatically, while LC3II/LC3I was also downregulated. The presence of oe-NUAK1 abrogated the effect of miR-1182 and let-7a mimic, as demonstrated by almost unchanged expression of Beclin1 and LC3 upon miR-1182 mimic + let-7a mimic + NUAK1 (Fig. 6c–e).

Collectively, overexpression of miR-1182 and let-7a promotes expression autophagy-related factor, enhancing autophagy while this result can be reversed by the up-regulation of NUAK1.

Up-regulated miR-1182 and let-7a inhibit tumor growth in vivo

To understand the in vivo role of miR-1182 and miR-let-7 in tumor growth, the CCA animal models were established, followed by treatment with miR-1182 agomir, and miR-let-7 agomir. Upon treatment, we regularly measured the volume and weight of mice and found the tumor volume and weight of mice treated with miR-1182 agomir and let-7a agomir was much smaller than that of mice treated agomir-NC. The volume and the quality of the nude mice were markedly decreased in mice after miR-1182 agomir + let-7a agomir treatment (Fig. 7a–c). Results from HE staining revealed that CCA mice had clumps around the bronchus and bronchioles with lung metastasis where the alveolar structure was destroyed, and the distal lung metastasis tumor tissue had atelectasis. Upon treatment with overexpression of miR-1182 and let-7a, the symptoms were alleviated and only small focal pulmonary metastatic tumors were seen around the bronchus and bronchioles with a small number of necrotic cells. After the combined treatment of miR-1182 agomir + let-7a agomir, the capillaries and interstitial small blood vessels in the lung tissue of nude mice were dilated and congested, whilst lung metastasis was attenuated (Fig. 7d). Besides, Western blot analysis indicated that relative to agomir-NC, miR-1182 agomir and let-7a agomir decreased NUAK1, MMP-2, and MMP-9 expression and their combined treatment resulted in lower expression (Fig. 7e). The above results support that the application of miR-1182 in combination with let-7a down-regulates NUAK1 expression, resulting in the inhibition of tumor growth in nude mice.

Discussion

CCA is the second most common primary hepatic malignancy, with an increasing incidence and mortality worldwide [23]. Early diagnosis is complicated due to the absence of specific symptoms during early stages of CCA, as a result of which most patients present at an advanced stage [24]. A thorough understanding of CCA shall therefore be prioritized. Our study revealed that miR-1182 and let-7a could play a role as tumor suppressors in CCA through the disruption of cell migration, invasion, proliferation, and autophagy by down-regulating NUAK1 expression. Furthermore, it has been previously proven that combination of miR-1182 and let-7a could have a synergistic inhibitory effect on CCA development.

One of the key findings from the present study showed that CCA tissues had a high expression of NUAK1. It has been suggested that NUAK1 was strongly associated with tumor invasion and migration, and also played an important role in tumor survival and progression [15]. Studies conducted on HCC have shown that high expression of NUAK1 has a positive regulatory effect on tumor size, histological differentiation, and TNM stage in HCC patients [25]; NUAK1 has also been identified as a promoter of invasion and migration in HCC cells through the regulation of epithelial mesenchymal transition [26]. Moreover, miR-145-regulated knockdown of NUAK1 reportedly leads to the inhibition of ICC cell proliferation, growth, and invasion, which contributed to clinical diagnosis and targeted therapy of ICC [16].

MiRNAs, such as hsa-miR-483-5p, hsa-miR-675, hsa-miR-139-3p, hsa-miR-598, hsa-miR-625 and hsa-miR-187, have a noteworthy involvement in cancer progression, due to their prognostic and predictive roles [27, 28]. In this study, CCA samples were observed to have low expressions of miR-1182 and let-7a. These two miRNAs have the potential to regulate NUAK1, in addition to their inhibitory action on cellular process. Both let-7a and miR-1182 have also been shown to be involved
Fig. 6 Up-regulated miR-1182 and let-7a induces cell autophagy. a MDC staining results (x400). b Statistical results of cell autophagy rate in each group. c The mRNA expression of Beclin1 and LC3 in HCCC-9810 and Huh28 cells measured by RT-qPCR. d The protein bands of Beclin1, LC3I, and LC3II determined by Western blot analysis. e Statistical results of the Beclin1, LC3I, and LC3II protein levels determined by Western blot analysis. *p < 0.05 vs. that of cells transfected with miR-NC or pc-DNA, †p < 0.05 vs. that of cells transfected with miR-1182 mimic or let-7a mimic, and & p < 0.05 vs. that of cells transfected miR-1182 mimic + let-7a mimic. The statistical data were measurement data and expressed as mean ± standard deviation. Comparisons among multiple groups were analyzed using ANOVA and followed by Tukey’s post hoc test. The experiment was repeated 3 times independently.
in tumorigenesis. Specifically, cervical cancer (CC) cells and tissues have significantly reduced let-7a expression, which promoted CC cell proliferation, migration and invasion by directly binding to 3′-untranslated region (UTRs) of pyruvate kinase muscle isozyme M2 (PKM2) [29]. Similarly, N Namwat et al. also revealed decreased let-7a expression in CCA samples [30]. Likewise, down-regulation of LINC00339, inhibited HCC cell growth, which in turn increased miR-1182 expression [31]. Additionally, other microRNAs, like miR-204, were found to have negative correlation with the expression of NUAK1, and miR-204 can act as a tumor suppressor in NSCLC tumor invasion through the down-regulation of NUAK1 [32]. Based on these results, it can be concluded that miR-1182 and let-7a have tumor suppressive effects on CCA via NUAK1 suppression.

Our study also revealed that elevated miR-1182 and let-7a down-regulated NUAK1 expression, resulted in the further inhibition of cell migration, invasion, proliferation as well as tumor growth and promoted autophagy. Several studies have looked into the relationship between miR-1182/let-7a and cell migration, invasion
and autophagy. As an example, overexpressed miR-1182 could suppress telomerase reverse transcriptase (hTERT) expression and proliferation and invasion in gastric cancer (GC) cells [33]. In a study focused on bladder cancer study, overexpressed miR-1182 inhibited proliferation, colony formation, and invasion of cancer cell [34]. Similar results related to let-7a were also reported in GC, breast cancer and cholesteatomas. Specifically, the overexpression of let-7a significantly suppressed the proliferation, migration, and invasion of GC cells by down-regulating PKM2 expression [35]. Other studies have highlighted the key contribution of let-7a in breast cancer cell and cholesteatoma keratinocytes: let-7a suppressed migration and invasion of breast cancer cell by downregulating CCR7 expression [36], while it acts as a suppressor of growth and invasion of cholesteatoma keratinocytes [37]. The overexpression of let-7a was examined in LPS-stimulated BV2 microglial cells, the results of which found that it promoted the induction of the autophagy-related proteins such as LC3II, Beclin1. These results evidently demonstrated its potential role in the autophagy process [38]. Consistent with the previous example, let-7a increases cellular autophagic level through the inhibition of Rictor expression in GC cells [39]. The autophagy-related proteins include LC3, Beclin 1, and p62; LC3 serves as a specific marker of autophagosome formation and Beclin 1 has been identified as an essential modifier of the autophagic process, which is also involved in tumor development [40]. In this study, the expressions of Beclin1 and LC3II/LC3I were higher following the overexpression of miR-1182 and let-7a; however, this finding can be reversed by the overexpression of NUAK1, suggesting that the up-regulation of miR-1182 and let-7a could improve CCA cell autophagy.

**Conclusion**

In conclusion, miR-1182 and let-7a could facilitate a novel aspect in the treatment of CCA patients, on which they were found to exert synergistic inhibitory effects on cell migration, invasion, proliferation, and a promoting effect on cell autophagy through the down-regulation of NUAK1 expression (Fig. 8). Nevertheless, the limitations in the current study involved the lack of report on the potential role of miR-1182 or let-7a in CCA progression, which shall be explored in further studies.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12935-021-01797-z.
Additional file 1: Table S1. STR profiling of CCC-S, HCCC-9810 and Huh28 cell lines

Additional file 2: Figure S1. Up-regulated miR-1182 and let-7a disrupt cell invasion and migration. A. Representative images of cell migration distance at 0 h and 24 h using scratch test upon treatment with miR NC, pc-DNA, miR-1182 mimic, let-7a mimic, miR-1182 mimic + let-7a mimic + NUPAK1 (scale bar = 250 μm). B. Representative images of cell invasion images using transwell assay upon treatment with miR NC, pc-DNA, miR-1182 mimic, let-7a mimic, miR-1182 mimic + let-7a mimic + NUPAK1 (scale bar = 50 μm).

Abbreviations
CCA: Cholangiocarcinoma; miRNAs: MicroRNAs; ICC: Intrahepatic cholangiocarcinoma; NSCLC: Non-small cell lung cancer; MMP: Matrix metalloproteinase; DEGs: Differentially expressed genes; GEO: Gene Expression Omnibus; TCGA: The Cancer Genome Atlas; TNM: Tumor nodes metastasis; STR: Short tandem repeat; DMEM: Dulbecco’s modified eagle medium; RT-qPCR: Reverse transcription quantitative polymerase chain reaction; WT: Wild type; MUT: Mutated; FBS: Fetal bovine serum; NC: Negative control; oe: Overexpression; SDS-PAGE: Sodium dodecyl sulfate-polyacrylamide gel electrophoresis; HRP: Horseradish peroxidase; IgG: Immunoglobulin G; RIP: RNA Binding Protein; Immunoprecipitation; RISC: RNA-induced silencing complex; CCK-8: Cell counting kit-8; MDC: Monodansylcadaverine; IHC: Immunohistochemistry; UTRs: Untranslated region; PKM2: Pyruvate kinase muscle isozyme M2; hTERT: Telomerase reverse transcriptase; GC: Gastric cancer; UTRs: Untranslated region; PKM2: Pyruvate kinase muscle isozyme M2; hTERT: Telomerase reverse transcriptase; GC: Gastric cancer.

Acknowledgements
We would like to give our sincere appreciation to the reviewers for their helpful comments on this article.

Authors’ contributions
XP and GW designed the study. GW and BW was involved in data collection. XP and BW performed the statistical analysis and preparation of Figures. XP and GW drafted the paper. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
The datasets generated/analysed during the current study are available.

Ethics approval and consent to participate
This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Institutional Animal Care and Use Committee of The Fourth Affiliated Hospital of China Medical University.

Consent for publication
Consent for publication was obtained from the participants.

Competing interests
The authors declare that they have no competing interests.

Received: 4 January 2020 Accepted: 27 January 2021
Published online: 09 March 2021

References
1. Lin KY, Ye H, Han BW, Wang WT, Wei PP, He B, et al. Genome-wide screen identified let-7c/miR-399a/miR-125b regulating tumor progression and stem-like properties in cholangiocarcinoma. Oncogene. 2016;35(26):3376–86.
2. Lu L, Byrnes K, Han C, Wang Y, Wu T. miR-21 targets 15-PGDH and promotes cholangiocarcinoma growth. Mol Cancer Res. 2014;12(6):890–900.
3. Li J, Gao B, Huang Z, Duan T, Li D, Zhang S, et al. Prognostic significance of microRNA-203 in cholangiocarcinoma. Int J Clin Exp Pathol. 2015;8(8):9512–6.
4. Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013;144(4):829–40.
5. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9933):2168–79.
6. Sawanyawisuth K, Wongkhiam C, Araki N, Zhao Q, Riggins GJ, Wongkhiam S. Serial analysis of gene expression reveals promising therapeutic targets for liver-fluke-associated cholangiocarcinoma. Asian Pac J Cancer Prev. 2012;13(Suppl):89–93.
7. Yang X, Wang W, Wang C, Wang L, Yang M, QM, et al. Characterization of EGFR family gene aberrations in cholangiocarcinoma. Oncol Rep. 2014;32(2):700–8.
8. Chen P, Li K, Liang Y, Li, L, Zhu X, High NUK1 expression correlates with poor prognosis and involved in NSCLC cells migration and invasion. Exp Lung Res. 2013;39(1):9–17.
9. Liu L, Ulbrich J, Muller J, Wustefeld T, Aebeler H, Kres T, et al. Deregulated MYC expression induces dependence upon AMPK-related kinase S. Nature. 2012;483(7391):668–12.
10. Ye XT, Guo AJ, Yin PF, Cao XD, Chang JC. Overexpression of NUPAK1 is associated with disease-free survival and overall survival in patients with gastric cancer. Med Oncol. 2014;31(7):61.
11. Chusorn P, Narnwatt N, Loolime T, Tazhasen A, Paroiraj K, Khuntikeo N, et al. Overexpression of miRNA-21 regulating PDCD4 during tumorigenesis of liver-fluke-associated cholangiocarcinoma contributes to tumor growth and metastasis. Tumour Biol. 2013;34(3):1579–88.
12. Zheng B, Jeong S, Zhu Y, Chen L, Xia Q, miRNA and IncRNA as biomarkers in cholangiocarcinoma(CCA). Oncotarget. 2017;8(59):10819–30.
13. Yang R, Chen Y, Yang C, Li, H, Wang B, Yan Q, et al. MicroRNA-144 suppresses cholangiocarcinoma cell proliferation and invasion through targeting platelet activating factor acetyhydrolase isoform 1b. BMC Cancer. 2014;14:917.
14. Frankel LB, Wen J, Lees M, Hoyer-Hansen M, Farkas T, Krogh A, et al. microRNA-101 is a potent inhibitor of autophagy. EMBO J. 2011;30(22):4626–41.
15. Huang X, Lu W, Zhang JH, Lu DL. miR-101 functions as a tumor suppressor gene by targeting NUPAK1 in pancreatic cancer. Int J Mol Med. 2014;34(6):1599–605.
16. Xiong X, Sun D, Cai H, Shan W, Yu Y, Pu L, et al. MiR-145 functions as a tumor suppressor targeting NUPAK1 in human intrahepatic cholangiocarcinoma. Biochem Biophys Res Commun. 2015;465(2):262–9.
17. Sasaki M, Nitta T, Sato Y, Nakamura Y. Autophagy may occur at an early stage of cholangiocarcinogenesis via biliary intraepithelial neoplasia. Hum Pathol. 2015;46(2):202–9.
18. Huang JL, Hezel AF. Autophagy in intra-hepatic cholangiocarcinoma. Autophagy. 2012;8(7):1148–9.
19. Puustinen P, Keldsbo A, Corcelle-Termeau E, Ngoei K, Sonder SL, Farkas T, et al. DNA-dependent protein kinase regulates lysosomal AMPK-dependent protein kinase activation and autophagy. Autophagy. 2020;16(10):1871–88.
20. Ye Z, Jin H, Qian Q, Aragoneta 2: a novel rising star in cancer research. Cancer. 2015;6(9):877–82.
21. Sheu-Gruttadauria J, MacRae U. Phase Transitions in the Assembly and Function of Human miRISC. Cell. 2018;173(4):946-57.e16.
22. Liu Y, Zhang H, Yan L, Du W, Zhang M, Chen H, et al. MiR-2 and MiR-9 contribute to the angiogenic effect produced by hypoxia/15-HETE in pulmonary endothelial cells. J Mol Cell Cardiol. 2018;121:36–50.
23. Yao D, Kunam VK, Li X. A review of the clinical diagnosis and therapy of cholangiocarcinoma. J Int Med Res. 2014;42(1):3–16.
24. Chamadol N, Paroiraj K, Khuntikeo N, Loolime T, Singthaworn P, et al. Histological confirmation of periductal fibrosis from ultrasound diagnosis in cholangiocarcinoma patients. J Hepatobiliary Pancreat Sci. 2014;21(5):316–22.
25. Cui J, Yu Y, Lu G, Liu C, Liu X, Xu YX, et al. Overexpression of ARK1 is associated with poor prognosis in hepatocellular carcinoma. Tumour Biol. 2013;34(3):191–3.
26. Ye Z, Chen X, Chen X. ARK1 promotes invasion and migration in hepatocellular carcinoma cells by regulating epithelial-mesenchymal transition. Oncol Lett. 2018;15(2):1511–6.
27. Wang M, Wen TF, He LE, Li C, Zhu WJ, Trishul NM. A six-microRNA set as prognostic indicators for bile duct cancer. Int J Clin Exp Med. 2015;8(10):17261–70.
28. Zhu Y, Chen X, Pan Q, Wang Y, Su S, Jiang C, et al. A Comprehensive proteomics analysis reveals a secretory path- and status-dependent signature of exosomes released from tumor-associated macrophages. J Proteome Res. 2015;14(10):4319–31.

29. Guo M, Zhao X, Yuan X, Jiang J, Li P. MiR-let-7a inhibits cell proliferation, migration, and invasion by down-regulating PKM2 in cervical cancer. Oncotarget. 2017;8(17):28226–36.

30. Namwat N, Chusorn P, Loilome W, Techasen A, Puetkasichonpasutha J, Parjojkul C, et al. Expression profiles of oncomir miR-21 and tumor suppressor let-7a in the progression of opisthorchiasis-associated cholangiocarcinoma. Asian Pac J Cancer Prev. 2012;13(Suppl):65–9.

31. Xiao J, Yu H, Ma Z. LINC00339 promotes growth and invasiveness of hepatocellular carcinoma by the miR-1182/SKA1 pathway. Onco Targets Ther. 2019;12:4481–8.

32. Shi L, Zhang B, Sun X, Lu S, Liu Z, Liu Y, et al. MiR-204 inhibits human NSCLC metastasis through suppression of NUAK1. Br J Cancer. 2014;111(12):2516–27.

33. Zhang D, Xiao YF, Zhang, JW, Xie R, Hu CJ, Tang B, et al. miR-1182 attenuates gastric cancer proliferation and metastasis by targeting the open reading frame of hTERT. Cancer Lett. 2015;360(2):151–9.

34. Zhou J, Dai W, Song J. miR-1182 inhibits growth and mediates the chemosensitivity of bladder cancer by targeting hTERT. Biochem Biophys Res Commun. 2016;470(2):445–52.

35. Tang R, Yang C, Ma X, Wang Y, Luo D, Huang C, et al. MiR-let-7a inhibits cell proliferation, migration, and invasion by down-regulating PKM2 in gastric cancer. Oncotarget. 2016;7(3):5972–84.

36. Kim SJ, Shin JY, Lee KD, Bae YK, Sung KW, Nam SJ, et al. MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7. Breast Cancer Res. 2012;14(1):R14.

37. Zhang W, Chen X, Qin Z. MicroRNA let-7a suppresses the growth and invasion of cholesteatom keratinocytes. Mol Med Rep. 2015;11(3):2097–103.

38. Song J, Oh Y, Lee JE. miR-Let7A modulates autophagy induction in LPS-activated microglia. Exp Neurobiol. 2015;24(2):117–25.

39. Fan H, Jiang M, Li B, He Y, Huang C, Luo D, et al. MicroRNA-let-7a regulates cell autophagy by targeting Rictor in gastric cancer cell lines MGC-803 and SGC-7901. Oncol Rep. 2018;39(3):1207–14.

40. Masuda GC, Yashiro M, Kitayama K, Miki Y, Kasahima H, Kinoshita H, et al. Clinicopathological correlations of autophagy-related proteins LC3, Beclin 1 and p62 in gastric cancer. Anticancer Res. 2016;36(1):129–36.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.